Short Interest in Cyclo Therapeutics, Inc. (NASDAQ:CYTH) Increases By 65.1%

Cyclo Therapeutics, Inc. (NASDAQ:CYTH) was the recipient of a significant growth in short interest in the month of April. As of April 15th, there was short interest totalling 75,300 shares, a growth of 65.1% from the March 31st total of 45,600 shares. Currently, 0.5% of the company’s shares are sold short. Based on an average trading volume of 106,700 shares, the days-to-cover ratio is presently 0.7 days.

Cyclo Therapeutics Stock Down 2.3 %

Shares of CYTH stock opened at $1.26 on Monday. The stock has a fifty day moving average of $1.48 and a 200 day moving average of $1.46. Cyclo Therapeutics has a 52 week low of $0.84 and a 52 week high of $2.57.

Cyclo Therapeutics (NASDAQ:CYTH) last posted its earnings results on Monday, March 18th. The company reported ($0.23) EPS for the quarter. Cyclo Therapeutics had a negative return on equity of 4,506.97% and a negative net margin of 1,864.03%. The company had revenue of $0.31 million during the quarter.

Wall Street Analysts Forecast Growth

Separately, Ascendiant Capital Markets initiated coverage on Cyclo Therapeutics in a research report on Monday, April 22nd. They set a “buy” rating and a $2.60 price target for the company.

Institutional Trading of Cyclo Therapeutics

A hedge fund recently bought a new stake in Cyclo Therapeutics stock. Founders Fund V Management LLC bought a new stake in Cyclo Therapeutics, Inc. (NASDAQ:CYTH) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 480,708 shares of the company’s stock, valued at approximately $764,000. Cyclo Therapeutics accounts for 80.8% of Founders Fund V Management LLC’s investment portfolio, making the stock its biggest holding. Founders Fund V Management LLC owned approximately 2.11% of Cyclo Therapeutics as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 68.55% of the company’s stock.

Cyclo Therapeutics Company Profile

Cyclo Therapeutics, Inc, a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease.